FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367303331> ?p ?o ?g. }

• W4367303331 abstract "<h3>Objective:</h3> Analyze impact of number of lifetime antiseizure medications (ASMs) on effectiveness and tolerability of brivaracetam (BRV) in adults with focal-onset seizures in a real-world clinical setting. <h3>Background:</h3> Increasing number of lifetime ASMs is associated with poorer response to newly administered ASM. <h3>Design/Methods:</h3> Pooled analysis of data from two 12-month, prospective, noninterventional studies (Europe: EP0077/NCT02687711; United States: EP0088) in patients initiating BRV as prescribed by their physician and followed for ≤12 months. Post hoc analysis included patients (≥18 years) with focal-onset seizures and ≥1 lifetime ASM at BRV initiation. Outcomes were assessed by number of lifetime ASMs (ASMs stopped before BRV initiation/ongoing at BRV initiation). <h3>Results:</h3> Of 720 included patients, 14.0%, 22.9%, 16.5%, and 46.5% had 1–2, 3–4, 5–6, and ≥7 lifetime ASMs, respectively. Across ASM subgroups, main reason for BRV initiation was lack of efficacy of current treatment (range: 73.3% [1–2 ASMs] to 89.0% [≥7 ASMs]). In patients with 1–2, 3–4, 5–6, and ≥7 lifetime ASMs, respectively, 12-month BRV retention was 68.3%, 66.1%, 55.5%, and 51.3%; 20.0%, 14.8%, 6.8%, and 2.7% had 12-month seizure freedom since baseline. Patients with 1–2 and 3–4 lifetime ASMs were less likely to discontinue BRV/terminate the study vs those with ≥5 lifetime ASMs. A lower proportion of patients with fewer lifetime ASMs discontinued BRV due to lack of efficacy (range: 1.0% [1–2 ASMs] to 14.9% [≥7 ASMs]) or treatment-emergent adverse events (TEAEs, 5.0% [1–2 ASMs] to 15.2% [≥7 ASMs]). In patients with 1–2, 3–4, 5–6, and ≥7 lifetime ASMs, respectively, TEAEs were reported in 26.7%, 37.0%, 46.2%, and 50.4%; 13.9%, 17.0%, 21.8%, and 30.1% discontinued due to TEAEs. <h3>Conclusions:</h3> Patients with fewer lifetime ASMs upon BRV initiation had numerically higher retention, and numerically lower incidences of TEAEs/discontinuations due to TEAEs. <b>Disclosure:</b> Dr. Martin has received personal compensation for serving as an employee of UCB. Dr. Martin has received stock or an ownership interest from UCB. Dr. Bourikas has nothing to disclose. Mrs. Brock has received personal compensation for serving as an employee of UCB. Dr. Dongre has received personal compensation for serving as an employee of UCB Inc. Dr. Dongre has stock in UCB Inc. Sami Elmoufti has nothing to disclose. Iryna Leunikava has nothing to disclose. Dr. Little has received personal compensation for serving as an employee of UCB. Anne-Liv Schulz has received personal compensation for serving as an employee of UCB. Anne-Liv Schulz has received stock or an ownership interest from UCB." @default.
• W4367303331 created "2023-04-29" @default.
• W4367303331 creator A5004699601 @default.
• W4367303331 creator A5006221493 @default.
• W4367303331 creator A5006832011 @default.
• W4367303331 creator A5034634819 @default.
• W4367303331 creator A5046288059 @default.
• W4367303331 creator A5053508092 @default.
• W4367303331 creator A5060170238 @default.
• W4367303331 creator A5074242701 @default.
• W4367303331 date "2023-04-25" @default.
• W4367303331 modified "2023-10-14" @default.
• W4367303331 title "Effectiveness and Tolerability of Brivaracetam by Number of Lifetime Antiseizure Medications in Adults with Focal Onset Seizures: Pooled Data From Two Real-world Studies (P11-1.010)" @default.
• W4367303331 doi "https://doi.org/10.1212/wnl.0000000000201878" @default.
• W4367303331 hasPublicationYear "2023" @default.
• W4367303331 type Work @default.
• W4367303331 citedByCount "0" @default.
• W4367303331 crossrefType "proceedings-article" @default.
• W4367303331 hasAuthorship W4367303331A5004699601 @default.
• W4367303331 hasAuthorship W4367303331A5006221493 @default.
• W4367303331 hasAuthorship W4367303331A5006832011 @default.
• W4367303331 hasAuthorship W4367303331A5034634819 @default.
• W4367303331 hasAuthorship W4367303331A5046288059 @default.
• W4367303331 hasAuthorship W4367303331A5053508092 @default.
• W4367303331 hasAuthorship W4367303331A5060170238 @default.
• W4367303331 hasAuthorship W4367303331A5074242701 @default.
• W4367303331 hasConcept C118552586 @default.
• W4367303331 hasConcept C126322002 @default.
• W4367303331 hasConcept C187212893 @default.
• W4367303331 hasConcept C197934379 @default.
• W4367303331 hasConcept C2778186239 @default.
• W4367303331 hasConcept C2778375690 @default.
• W4367303331 hasConcept C71924100 @default.
• W4367303331 hasConceptScore W4367303331C118552586 @default.
• W4367303331 hasConceptScore W4367303331C126322002 @default.
• W4367303331 hasConceptScore W4367303331C187212893 @default.
• W4367303331 hasConceptScore W4367303331C197934379 @default.
• W4367303331 hasConceptScore W4367303331C2778186239 @default.
• W4367303331 hasConceptScore W4367303331C2778375690 @default.
• W4367303331 hasConceptScore W4367303331C71924100 @default.
• W4367303331 hasLocation W43673033311 @default.
• W4367303331 hasOpenAccess W4367303331 @default.
• W4367303331 hasPrimaryLocation W43673033311 @default.
• W4367303331 hasRelatedWork W2023356695 @default.
• W4367303331 hasRelatedWork W2029053154 @default.
• W4367303331 hasRelatedWork W2070415323 @default.
• W4367303331 hasRelatedWork W2076881486 @default.
• W4367303331 hasRelatedWork W2100415039 @default.
• W4367303331 hasRelatedWork W2409130183 @default.
• W4367303331 hasRelatedWork W2755222529 @default.
• W4367303331 hasRelatedWork W2793900558 @default.
• W4367303331 hasRelatedWork W2955353433 @default.
• W4367303331 hasRelatedWork W3089252390 @default.
• W4367303331 isParatext "false" @default.
• W4367303331 isRetracted "false" @default.
• W4367303331 workType "article" @default.